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ABSTRACT
Objective: Accurate, efficient and cost-effective
disposition of patients presenting to emergency
departments (EDs) with symptoms suggestive of acute
coronary syndromes (ACS) is a growing priority. Platelet
activation is an early feature in the pathogenesis of ACS;
thus, we sought to obtain an insight into whether point-
of-care testing of platelet function: (1) may assist in the
rule-out of ACS; (2) may provide additional predictive
value in identifying patients with non-cardiac symptoms
versus ACS-positive patients and (3) is logistically
feasible in the ED.
Design: Prospective cohort feasibility study.
Setting: Two urban tertiary care sites, one located in the
USA and the second in Argentina.
Participants: 509 adult patients presenting with
symptoms of ACS.
Main outcome measures: Platelet reactivity was
quantified using the Platelet Function Analyzer-100, with
closure time (seconds required for blood, aspirated under
high shear, to occlude a 150 µm aperture) serving as the
primary endpoint. Closure times were categorised as
‘normal’ or ‘prolonged’, defined objectively as the 90th
centile of the distribution for all participants enrolled in
the study. Diagnosis of ACS was made using the
standard criteria. The use of antiplatelet agents was not
an exclusion criterion.
Results: Closure times for the study population ranged
from 47 to 300 s, with a 90th centile value of 138 s. The
proportion of patients with closure times ≥138 s was
significantly higher in patients with non-cardiac
symptoms (41/330; 12.4%) versus the ACS-positive
cohort (2/105 (1.9%); p=0.0006). The specificity of
‘prolonged’ closure times (≥138 s) for a diagnosis of
non-cardiac symptoms was 98.1%, with a positive
predictive value of 95.4%. Multivariate analysis revealed
that the closure time provided incremental, independent
predictive value in the rule-out of ACS.
Conclusions: Point-of-care assessment of platelet
reactivity is feasible in the ED and may facilitate the rapid
rule-out of ACS in patients with prolonged closure times.
Accurate, efﬁcient and cost-effective diag-
nosis of patients presenting to emergency
departments (EDs) with symptoms suggestive
of acute coronary syndromes (ACS)—and, in
particular, the exclusion and early discharge
of patients with non-cardiac chest pain—is a
growing priority.
12In an effort to meet this
challenge, interest has focused on the identi-
ﬁcation of new approaches to augment the
standard ED procedures and facilitate the
timely triage of patients with suspected ACS.
For example, there is recent evidence that
coronary CT angiography (CCTA) combined
with routine clinical assessment may provide
added prognostic value in the management
of chest pain patients in the ED.
3–8 Use of
Strengths and limitations of this study
▪ The study suggests that a technically straightfor-
ward and cost-effective test, with minimal patient
risk, may serve as a useful adjunct to the current,
standard emergency department practices for the
rule-out of acute coronary syndromes. Importantly,
the results are generalisable: the observation of a
higher incidence of prolonged closure times in
patients with non-cardiac symptoms was seen in
participants from two distinct healthcare systems
and populations.
▪ Platelet Function Analyzer-100 testing will only
contribute to the identification of a subset of
patients with non-cardiac symptoms, with the
size of the subset and the potential value of the
test dependent on the threshold used to define
the ‘prolonged’ closure times.
▪ Limitations of this pilot study include the enrol-
ment of patients via convenience sampling, the
fact that patient outcomes were not monitored
beyond hospital discharge and that a risk/benefit
analysis was not included in the study design.
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safe and reduces ED costs and hospital length of stay.
3–5
78However, these beneﬁts are accompanied by expos-
ure to radiation and associated with increases in diagnos-
tic testing and subsequent invasive procedures.
58
Assessment of platelet activation, an early feature in the
pathogenesis of ACS,
9–14 has also been investigated as a pos-
s i b l eb e n i g ns t r a t e g yt oe x p e d i t et h ed i a g n o s i so fA C S .
15 16
Application of ﬂow cytometry, the ‘gold standard’ for the
quantitation of molecular indices of platelet activation, is,
however, impractical for routine use under emergent condi-
tions.
11 12 17 18 More importantly, classic molecular indices
of platelet activation have not provided added beneﬁti nt h e
risk stratiﬁcation of undifferentiated chest pain patients.
15 16
We hypothesised that rapid assessment of platelet reactiv-
ity using a technically straightforward point-of-care device—
speciﬁcally, the Platelet Function Analyzer (PFA)-100
(Siemens)—may represent a more feasible strategy to assist
in the timely rule-out of ACS in the ED. Rather than quanti-
fying molecular markers of platelet activation-aggregation,
the output of the PFA-100 is the ‘closure time’:t h a ti s ,t h e
time required for whole blood, aspirated under high shear,
to occlude a small, 150 μm aperture in a membrane coated
with standard platelet agonists (collagen-ADP or
collagen-epinephrine). Although the PFA-100 is typically
utilised to investigate the responsiveness of patients to
aspirin and other antiplatelet therapies and aid in the
detection of platelet dysfunction,
11 12 18–22, there is evidence
to suggest that shortened closure times may be a marker of
the acuity of coronary disease.
10 Accordingly, our primary
aims in this pilot study were to determine whether
point-of-care testing of platelet function: (1) may assist in
the rule-out of ACS; (2) may yield additional predictive
value in identifying patients with non-cardiac symptoms
versus ACS-positive patients and (3) is logistically feasible in
an emergent setting. In addition, as a secondary analysis, we
investigated whether the closure time may be of value in dis-
criminating between ST-elevation myocardial infarction
(STEMI) and non-ST-elevation myocardial infarction
(NSTEMI)/unstable angina (UA).
METHODS
We conducted a prospective cohort feasibility study of
patients presenting with potential ACS at two urban ter-
tiary care sites: the ED at the University of Massachusetts
(UMASS)-Memorial Medical Center, University Campus,
Worcester, Massachusetts, USA, and the Cardiology
Department, Instituto Modelo de Cardiologia Privado
SRL, Cordoba, Argentina. The enrolment period was
from January 2007 to December 2010. At each site,
patients were entered on a convenience basis: that is,
enrolments were not consecutive but, rather, coincided
with the work schedules of the study investigators.
Patient population
Patients ≥18 years of age with a potential diagnosis of ACS
(at the discretion of the treating physician and reﬂected
by orders for an ECG and cardiac biomarkers) were con-
sidered for enrolment in the study. The prospective exclu-
sion criteria were pregnancy, renal insufﬁciency (deﬁned
as serum creatine levels ≥1.5 mg/dL), anaemia (haemato-
crit <30%), platelet count <100 000/µL, major bleeding,
any gastrointestinal bleeding, trauma or the inability to
provide informed consent for any reason. The use of anti-
platelet agents was not an exclusion criterion.
Study enrolment and protocol
As soon as possible after evaluation by ED staff, potential
participants were approached for enrolment into the
study. If the patient was too ill or otherwise unable to
provide written consent, then proxy consent was
attempted. If consent was obtained by proxy and the
patient later became cognisant, they were given the
option to continue or withdraw their participation in
the study. If consent was withdrawn, all collected data
were discarded.
Blood used in the PFA-100 was drawn within <1 h after
presentation, at the same time as cardiac biomarker
testing, and the closure time was measured within 3 h of
collection. All samples were obtained via peripheral veni-
puncture and drawn into tubes containing 3.2% sodium
citrate. Immediately before analysis, each sample was
gently inverted; a 900 μL aliquot of whole blood was
then applied to a collagen-ADP test cartridge and the
closure time was quantiﬁed. Maximum test duration for
the PFA-100 is 5 min; if the aperture is not occluded
within this period, a closure time of ‘>300 s’ is displayed.
On enrolment, patients were questioned regarding a
history of bleeding or platelet function disorders and
ingestion of known antiplatelet agents within the past
7 days (aspirin, clopidogrel, non-steroidal anti-
inﬂammatory agents). In addition, the medical record
was reviewed and the standard cardiac risk factors (dia-
betes, hypertension, hypercholesterolaemia, smoking,
family history of heart disease) were recorded and used
in the calculation of thrombolysis in myocardial infarc-
tion (TIMI) risk score.
23
Patient diagnosis
The ﬁnal diagnosis (non-cardiac symptoms vs
ACS-positive) was established via a standardised chart
review. All reviews were conducted by physicians in a
blinded manner, without knowledge of the closure time
data. For participants enrolled at the Instituto Modelo
de Cardiologia Privado, patients were seen by a cardiolo-
gist at the time of hospital presentation, and all reviews
were performed by a team of cardiologists (WQ-C, GFT,
FRZ, ECC and JPS). At UMASS, each patient was ﬁrst
seen by an Emergency Medicine physician at the time of
hospital presentation, and each chart was reviewed by an
ED physician (CED). For patients with a deﬁnitive diag-
nosis of non-cardiac symptoms (ie, patients with no
ischaemic ECG changes, no positive markers or provoca-
tive cardiovascular test results, and no history of a diag-
nosis of ACS of any type in the chart), no additional
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had positive cardiac biomarkers during admission; (2)
underwent cardiac catheterisation; (3) had a positive
provocative cardiovascular test (eg, exercise stress test)
or (4) had ischaemic ECG changes, the chart was
reviewed by an ED physician and a cardiologist. In any
case in which the diagnosis was uncertain, the decision
was adjudicated by a cardiologist (CSS).
Patients considered to be ACS positive were categorised
into one of the two groups, STEMI or NSTEMI/UA, in
accordance with the standard guidelines.
24–26 Patients who
did not meet these criteria were classiﬁed as having a diag-
nosis of non-cardiac chest pain/symptoms.
Statistical analysis
Our target sample size in this exploratory study was
empiric. We reasoned that, as an approximate order of
magnitude, ∼100 patients would be required in the
ACS-positive group in order to have the likelihood of dis-
cerning a potential difference in the closure times
between patients with non-cardiac symptoms and the
ACS-positive cohort. Assuming that 75% of patients
enrolled in the study would have a diagnosis of non-
cardiac chest pain (and thus 25% would be ACS posi-
tive), a total of approximately 400 patients would be
required. To account for exclusions, target enrolment
was set at ∼500 participants.
Univariate comparisons
Our primary analyses focused on the comparison of
patients in the two main outcome groups: non-cardiac
symptoms versus ACS positive. All categorical data were
compared using the Fisher’s exact test and are reported
as percentages. For continuous data, the D’Agostino and
Pearson test was applied to determine normality and the
appropriate parametric (t test) or non-parametric alter-
native (Mann-Whitney) tests were utilised. Secondary
analysis (comparison of closure times among non-
cardiac chest pain, STEMI and NSTEMI/UA groups)
was conducted using the Kruskal-Wallis test. Results are
reported as mean±SD or medians with associated 10th
and 90th centile ranges.
Sensitivity, specificity and multivariate analysis
We made the prospective and arbitrary decision to cat-
egorise the closure time into ‘normal’ and “prolonged”
values based on the 90th centile of the distribution for
all patients enrolled in the study. Utilising the normal
and prolonged values of closure time, the sensitivity, spe-
ciﬁcity, negative and positive predictive values and likeli-
hood ratio for identifying patients with non-cardiac
symptoms were determined. Two reasons contributed to
our choice of non-cardiac chest pain (rather than
ACS positive) as the main outcome of interest: (1) this
approach is consistent with current guidelines for the
improvement of diagnostic accuracy
18and (2) we rea-
soned that prolonged closure times may be associated
with the absence of ACS, whereas shorter closure times
may be manifest in either group of patients. Sensitivity,
speciﬁcity, predictive values and the likelihood ratio are
reported with associated 95% CIs.
To determine whether the PFA closure time provides
an additional predictive value to the standard clinical
diagnostic information, a logistic regression was devel-
oped to assess its independent association with the main
outcome of non-cardiac symptoms. Independent pre-
dictor variables considered to be mandatory in the
model were the closure time (utilising continuous rather
than the categorised values; the main predictor of inter-
est) and the TIMI risk score (representing standard clin-
ical information to predict ACS outcomes). To account
for potential differences between UMASS and Cordoba,
the study site was also added to the regression model.
Other non-mandatory variables considered for inclusion
were sex, a medical history of diabetes, hypertension,
hypercholesterolaemia, smoking and clopidogrel use. As
age and aspirin use are individually incorporated in the
TIMI risk score, these variables were not considered for
separate inclusion in the model. Non-mandatory vari-
ables were left in the model only if they yielded an
increase in predictive value as determined by receiver
operating characteristic (ROC) analysis or were of add-
itional importance based on the 2 log-likelihood ratio
test.
The reported estimate and adjusted OR for closure time
were calculated for an increase in platelet closure time of
10 s (rather than 1 s), a choice based on the premise that
a 1 s increase would be of limited clinical usefulness. The
ﬁnal model was evaluated by c-statistic (area under the
ROC curve) and the Hosmer and Lemeshow ﬁt test. As a
sensitivity test, the results were calculated using the
general estimating equation (PROC GENMOD) with study
site evaluated as a subject factor (cluster) rather than a
term in the model. The Net Reclassiﬁcation Index (NRI)
and Integrated Discrimination Improvement (IDI) statistic
were not included in the analyses, given the scepticism
and criticisms that have been raised concerning their
value in predicting the potential, incremental prognostic
impact of novel biomarkers.
27 28
Analyses were performed using GraphPad Prism V.5.04
(San Diego, California, USA) and SAS V.9.3 (Carey,
North Carolina, USA).
RESULTS
Enrolment and exclusions
A combined total of 509 patients were enrolled at the
two study sites (ﬁgure 1). Sixty-one participants were
excluded because the closure time data were not
available. The reasons included technical errors
(n=14), closure times >300 s (possibly due to mild
thrombocytopenia, anaemia or inadequate mixing of
the blood sample prior to testing; n=36) and failure
to measure the closure time despite obtaining
consent (n=11). An additional ﬁve participants were
removed from analysis because exclusion criteria were
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consent was revoked after the blood sample was col-
lected (n=1). For the remaining 443 patients in
whom the closure time was quantiﬁed, 8 were diag-
nosed with thrombotic events that were non-cardiac in
origin and thus were excluded from further analysis.
Accordingly, results are reported for 435 participants
(324 enrolled at UMASS and 111 enrolled in
Cordoba): 105 were diagnosed with ACS and 330 had
non-cardiac symptoms.
Demographics
As expected,
29 the ACS-positive group had higher TIMI
scores, was older, and had a higher proportion of male
participants versus patients with non-cardiac symptoms
(table 1). In addition, the incidence of hypercholesterol-
aemia and the use of clopidogrel were signiﬁcantly
higher in the ACS group. There were, however, no dif-
ferences in the use of aspirin, incidence of hypertension
or diabetes, proportion of smokers or a reported family
history of heart disease between the two groups.
Figure 1 Inclusion flow chart.
Table 1 Demographics: all patients
Non-cardiac symptoms (total n=330) ACS positive (total n=105) p Value
Age (years): mean±SD 57±14 (n=328) 61±13 (n=104) 0.034
Male 65% (n=330) 80% (n=105) 0.004
TIMI score: mean±SD 1.9±1.4 (n=320) 3.1±1.4 (n=104) <0.0001
Aspirin 71% (n=321) 64% (n=104) 0.222 (ns)
Clopidogrel 11% (n=325) 20% (n=104) 0.031
Smoker 29% (n=322) 28% (n=105) 0.901(ns)
Hypertension 57% (n=322) 62% (n=105) 0.425 (ns)
Hypercholesterolaemia 57% (n=322) 69% (n=105) 0.030
Diabetes 24% (n=322) 27% (n=105) 0.601 (ns)
Family history 40% (n=319) 41% (n=105) 0.909 (ns)
ACS, acute coronary syndromes; TIMI, thrombolysis in myocardial infarction.
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There was a modest but signiﬁcant difference in the
median closure times in patients with non-cardiac symp-
toms versus the ACS-positive group: 91 vs 87 s, respect-
ively (p=0.0061; ﬁgure 2A). When the ACS-positive
group was divided into STEMI and combined NSTEMI/
UA cohorts, the modest differences in the closure time
in the secondary three-group analysis remained signiﬁ-
cant (p=0.0001; ﬁgure 2C).
Of potentially greater importance, patients with non-
cardiac symptoms versus ACS-positive patients were dis-
tinguished by differences in the proportion of the pro-
longed closure times. We found that 41/330 (12.4%) of
patients with non-cardiac symptoms had closure times
≥138 s (ie, the 90th centile of the distribution for all
patients enrolled in the study) while, in contrast, 2/105
(1.9%) of patients in the ACS-positive group had closure
times ≥ this value (p=0.0006; ﬁgure 2B and table 2).
The speciﬁcity and sensitivity of ‘prolonged’ closure
times (≥138 s) for a diagnosis of non-cardiac symptoms
were 98.1% and 12.4%, respectively, with a positive pre-
dictive value of 95.4%, a negative predictive value of
26.3% and a likelihood ratio of 6.52 (table 3).
Site differences: UMASS versus Cordoba
Patients at both sites displayed the expected differences
in TIMI score, age and sex between non-cardiac chest
pain and ACS-positive groups (data not shown).
However, the participants enrolled in Cordoba were sig-
niﬁcantly younger, with a higher proportion of males
Figure 2 Platelet Function
Analyzer-100 closure time (s). (A)
Median values with 10th, 25th,
75th and 90th centiles: acute
coronary syndromes
(ACS)-positive patients and
patients with non-cardiac
symptoms. (B) Individual data
points for all participants:
ACS-positive patients and
patients with non-cardiac
symptoms. Lines denote the 80th,
90th and 95th centiles of closure
times for all patients enrolled in
the study. (C) Individual data
points for all participants:
ST-elevation myocardial
infarction, non-ST-elevation
myocardial infarction/unstable
angina cohorts and patients with
non-cardiac symptoms. Lines
denote the 80th, 90th and 95th
centiles of closure times for all
patients enrolled in the study.
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betes, when compared with UMASS (table 4). In add-
ition, and as expected,
30 31 aspirin use was signiﬁcantly
lower among the cohort in Cordoba versus the UMASS
population (40% vs 80%, p<0.0001, table 4). Despite
these demographic differences, a higher incidence of
prolonged closure times in patients with non-cardiac
symptoms was observed at both sites: that is, the propor-
tion of participants with closure times ≥138 s was 13% vs
10% in patients with non-cardiac chest pain and 1.9% vs
2% in ACS-positive patients at UMASS versus Cordoba,
respectively.
Closure time as an independent predictor of diagnosis
Logistic regression analysis was ﬁrst performed with manda-
tory variables (closure time, TIMI risk score) and non-
mandatory variables (study site, sex, diabetes, hypertension,
hypercholesterolaemia, smoking, clopidogrel use) included
in the regression model (data not shown). ROC analysis
revealed that, among the non-mandatory variables, only
study site (UMASS vs Cordoba) contributed to an increase
to the predictive value of the model for a diagnosis of non-
cardiac symptoms. Comparison of ROC curves obtained by
including the closure time, TIMI score and site in the
model versus TIMI score and site alone showed a signiﬁ-
cant, incremental increase in area under the curve with the
addition of closure time (0.818 vs 0.795; p=0.009; ﬁgure 3).
Accordingly, the ﬁnal multivariate logistic regression model
incorporated these three variables (table 5).
For every 10 s increase in the closure time, the
adjusted odds of a diagnosis of non-cardiac symptoms
was 1.17 (95% CI 1.06 to 1.29; table 5). That is, when
controlling for TIMI risk score and study site: for every
10 s increase, the prolonged closure time was associated
with a 17% increase in the patient having non-cardiac
chest pain. These results demonstrate that, irrespective of
TIMI score and site, the closure time was associated with
the diagnosis of non-cardiac symptoms, with closure time
providing additional, incremental predictive value beyond that
obtained by TIMI score. The model demonstrated good
predictive characteristics (c=0.82) and model ﬁt
(χ
2=5.24, df=8; p=0.73). Finally, the sensitivity analysis
that utilised a general estimating equation accounting
for potential correlations among sites did not result in
any important changes in the direction of the effects
(adjusted odds for every 10 s increase in closure time:
1.15 with 95% CI 1.10 to 1.23) or conclusions.
DISCUSSION
In this study, we demonstrate that point-of-care testing of
platelet reactivity using the PFA-100 is feasible in the envir-
onment of the ED. The results of our primary analysis
revealed differences in closure times between patients with
non-cardiac symptoms versus ACS-positive cohorts, with
the most notable, discriminating feature being the higher
incidence of prolonged closure times in the group with
non-cardiac chest pain. Finally, the outcome of our multi-
variate analysis is consistent with the concept that the
assessment of closure time provides incremental, inde-
pendent prognostic value beyond that obtained using the
standard clinical predictor of TIMI score.
Assessment of platelet reactivity as a diagnostic tool for
ACS in emergent settings
It is well-established that heightened platelet activity
occurs in the setting of ACS.
9–11 13 14 32 Indeed, meas-
urement of platelet reactivity has been utilised in an
effort to discern the stability of coronary disease,
10
predict the future incidence and outcomes of major
adverse cardiovascular events,
11 33–37 and, although
results have been disappointing, guide the dosing of
antiplatelet agents with the goal of improving out-
comes.
32 38 39 Our current study differs from these previ-
ous reports, in that it focused on the assessment of
platelet reactivity as an adjunct strategy to risk stratify
patients with potential ACS in emergent conditions.
Accordingly, the novelty of our study lies in our
expanded analysis of the closure time, and the identiﬁ-
cation of a more practical and feasible application of
these data in the prognosis of ACS.
Our observation of a modest but signiﬁcant reduction
in the median/mean closure times in patients with ACS
is consistent with the outcomes of two previous, small
ED studies.
40 41 However, this ∼4 s difference is of a
limited practical signiﬁcance given the broad and over-
lapping distributions of closure times for patients with
non-cardiac symptoms and the ACS-positive cohort
(ﬁgure 2). Rather, we propose that the clinical utility of
Table 2 Incidence of prolonged closure time (≥138 s,
defined as the 90th centile of the distribution of the study
population)
Non-cardiac
symptoms
ACS
positive Total
Prolonged
closure time
Yes 41 2 43
No 289 103 392
Total 330 105 435
ACS, acute coronary syndromes.
Table 3 Sensitivity, specificity, positive and negative
predictive values and likelihood ratio of prolonged closure
time for a diagnosis of non-cardiac symptoms
95% CI
Sensitivity (%) 12.4 9.1 to 16.5
Specificity (%) 98.1 93.3 to 99.8
Positive predictive value (%) 95.4 84.2 to 99.4
Negative predictive value (%) 26.3 22.0 to 30.9
Likelihood ratio 6.52 1.61 to 26.51
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closure time, a threshold that we objectively deﬁned as the
90th centile of the distribution of the study population.
In this regard, we found that the prolonged closure time
(≥138 s) had a high speciﬁcity, positive predictive value
and likelihood ratio for a diagnosis of non-cardiac chest
pain.
Strengths and weaknesses
The results of our pilot study are consistent with the
hypothesis that point-of-care testing of platelet reactivity
may assist in the timely rule-out of ACS in the ED.
Strengths of this approach include the fact that the
assessment of closure time is technically straightforward
and cost effective, with minimal patient risk (ie, does
not involve exposure to radiation or additional invasive
testing). In addition, our data suggest that the concept is
generalisable. We observed signiﬁcant differences in
demographics (age and gender), the prevalence of spe-
ciﬁc risk factors (diabetes, smoking) and the use of anti-
platelet therapy (aspirin: table 4) between UMASS and
Cordoba—ﬁndings that are in agreement with the pub-
lished reports focused on Argentine cohorts,
30 31 42 and
may underlie the robust contribution of study site as a
predictor of outcome in our logistic regression model.
Nonetheless, our results, obtained from two distinct
healthcare systems and populations, consistently revealed
a higher proportion of prolonged closure times in
patients with non-cardiac symptoms.
There is, however, an important caveat to this strategy.
PFA testing will only contribute to the identiﬁcation of a
subset of patients with non-cardiac symptoms, with the
size of the subset and the potential value of the test
dependent on the threshold used to deﬁne ‘prolonged’
closure times (ﬁgure 2 and table 6). For example, the
prospective and arbitrary criterion used in our analysis
(the 90th centile of closure times for all patients
enrolled in the study) discerned an arguably modest
12.4% of patients with a diagnosis of non-cardiac symp-
toms. However, expediting the discharge of even a small
proportion of patients with a non-cardiac diagnosis
would limit the costs, potential risks and patient stress
associated with unneeded advanced diagnostic testing
and possibly invasive procedures.
12Reducing the thresh-
old (ie, to the 80th centile of the distribution) would
Table 4 Demographics: UMASS vs Cordoba
UMASS all (total n=324) Cordoba all (total n=111) p Value
Age (years): mean±SD 59±14 (n=324) 56±12 (n=108) 0.036
Male 65% (n=324) 78% (n=111) 0.009
TIMI score: mean±SD 2.3±1.5 (n=313) 2.0±1.4 (n=111) 0.142 (ns)
Aspirin 80% (n=314) 40% (n=104) <0.0001
Clopidogrel 15% (n=319) 9% (n=111) 0.146 (ns)
Smoker 26% (n=316) 37% (n=111) 0.038
Hypertension 61% (n=316) 51% (n=111) 0.093 (ns)
Hypercholesterolaemia 62% (n=316) 53% (n=111) 0.115 (ns)
Diabetes 28% (n=313) 14% (n=111) 0.005
Family History 44% (n=313) 31% (n=51) 0.014
TIMI, thrombolysis in myocardial infarction.
Table 5 Multivariable logistic regression model (outcome
modeled: non-cardiac symptoms)
Predictor Adjusted OR 95% CI
Closure time 1.17 1.06 to 1.29
TIMI risk score 0.48 0.40 to 0.59
Study site 7.21 4.05 to 12.86
(UMASS vs Cordoba).
TIMI, thrombolysis in myocardial infarction.
Figure 3 Receiver operating characteristic (ROC) analysis.
Comparison of ROC curves obtained by including the closure
time, thrombolysis in myocardial infarction (TIMI) score and
study site in the regression model versus the TIMI score and
site alone showing a significant, incremental increase in area
under the curve with the addition of closure time (0.818 vs
0.795; p=0.009).
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Open Accessincrease the size of the subset identiﬁed as ACS negative,
with an accompanying (and increasingly unacceptable)
loss in speciﬁcity because of the growing proportion of
false positives (ACS-positive patients with prolonged
closure times: ﬁgure 2 and table 6). In contrast, increas-
ing the threshold (ie, to the 95th centile) would identify
a diminishing proportion of patients with non-cardiac
symptoms with an increasing speciﬁcity (ﬁgure 2 and
table 6). The appropriate deﬁnition of ‘prolonged’
closure time will therefore require reﬁnement based on
risk/beneﬁt analysis.
Finally, we emphasise that point-of-case assessment of
platelet reactivity and identiﬁcation of patients with ‘pro-
longed’ closure times clearly cannot function as a
stand-alone test for the rule-out of ACS. Rather, measure-
ment of PFA closure times may serve as an adjunct to the
current, standard ED practices. In support of this concept,
our multivariate logistic regression model revealed that,
irrespective of the TIMI score and study site (and, thus,
irrespective of differences in demographics and aspirin
use between sites), closure time was an independent pre-
dictor of the diagnosis of non-cardiac symptoms.
Summary, limitations and future directions
We report that measurement of the closure time using
the PFA-100 provides additional and independent, incre-
mental predictive value in the rule-out of ACS.
Limitations of this pilot feasibility study include the
enrolment of patients via convenience sampling, and dif-
ferences in the logistics of the chart review process
between the two sites. In addition, neither monitoring
of patient outcomes beyond hospital discharge (raising
the possibility of potential misclassiﬁcation of some
patients) nor risk/beneﬁt analysis of PFA testing was
incorporated into the study design. We emphasise that
point-of-care assessment of platelet reactivity cannot
serve as a stand-alone test to either discern patients with
non-cardiac symptoms versus ACS-positive patients or
distinguish between STEMI versus NSTEMI/UA in the
emergent setting—limitations that in all likelihood
reﬂect the complex and multifactorial pathophysiology
of acute myocardial ischaemia and infarction. Rather,
our results suggest that the assessment of closure times
may provide beneﬁt by augmenting the standard ED
diagnostic practices, a concept that warrants further
large-scale multicentre investigation.
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